Asthma treatment preference study -: A conjoint analysis of preferred drug treatments
Asthma treatment preference study -: A conjoint analysis of preferred drug treatments
复制标题
DOI：
10.1378/chest.125.3.916
复制
发表时间：
2004-03-01
期刊：
影响因子：
9.6
通讯作者：
Berggren, F
中科院分区：
文献类型：
--
作者：
Johansson, G;Ställberg, B;Berggren, F
目的：哮喘treatments.Methods的属性的患者偏好的评估：二百九十八例患者（年龄范围，18至60岁）从15个中心在瑞典完成了一份问卷调查，关于他们的哮喘，并排名18个替代治疗联合分析。患者接受吸入性皮质类固醇（ICS）和短效支气管扩张剂（n = 123）或ICS和长效支气管扩张剂（单独吸入器，n = 87;复方吸入器，n = 88）治疗。分析的属性是维持治疗，额外的救济，发病时间和救济的持续时间，每月的无菌天数（SFD）的数量，和每月的自付cost.Results;联合分析显示，最重要的方面的治疗是SFD。40%的患者每月少于或等于15个SFD。85%的患者更喜欢另一种治疗而不是目前的治疗。治疗偏好是异质性的，78%的患者没有被当前的治疗指南所覆盖。共有148名患者（50%）更喜欢组合吸入器，而不是单独的吸入器，233名患者（78%）更喜欢快速和长效的缓解剂。最优选的治疗是用于维持和缓解的复方吸入剂。平均而言，患者愿意支付额外的328瑞典克朗[36美元]每月的变化，以首选treatment.Conclusion：SFD是最重要的属性在哮喘治疗。患者愿意为转换到他们喜欢的治疗而付费。最受欢迎的治疗方法是快速长效的缓解治疗和用于维持和按需使用的组合吸入器。
Objective: Assessment of patient preferences for attributes of asthma treatments.Methods: Two hundred ninety-eight patients (age range, 18 to 60 years) from 15 centers in Sweden completed a questionnaire concerning their asthma, and ranked 18 alternative treatments using conjoint analysis. Patients were receiving treatment with either inhaled corticosteroids (ICS) and short-acting bronchodilator (n = 123) or ICS and long-acting bronchodilator (separate inhalers, n = 87; combination inhaler, n = 88). Attributes analyzed were maintenance treatment, additional reliever, time to onset and duration of reliever, number of symptom-free days (SFDs) per month, and out-of-pocket cost per month.Results; Conjoint analysis showed that the most important aspect of treatment was SFD. Forty percent of the patients had less than or equal to 15 SFDs per month. Eighty-five percent of the patients preferred another treatment over their current treatment. Treatment preferences were heterogeneous, and in 78% were not covered by current treatment guidelines. A total of 148 patients (50%) preferred a combination inhaler to separate inhalers, and 233 patients (78%) preferred a reliever that is both rapid and long acting. The most preferred treatment was a combination inhaler for maintenance and reliever use. On average, the patients were willing to pay an additional 328 Swedish krona [US $36] per month for the change to the preferred treatment.Conclusion: SFDs were the most important attribute in asthma treatment. Patients were willing to pay for a switch to their preferred treatment. The most favored treatments were a reliever therapy that is both rapid and long acting and a combination inhaler for both maintenance and as-needed use.